Molecular Diagnostics for Gonorrhoea: Implications for Antimicrobial Resistance and the Threat of Untreatable Gonorrhoea

PLoS Medicine

Volumn 11, Issue 2, 2014, Pages

  Low, Nicola ^a   Unemo, Magnus ^b   Skov Jensen, Jørgen ^c   Breuer, Judith ^d   Stephenson, Judith M ^e  

^a UNIVERSITY OF BERN   (Switzerland)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c STATENS SERUM INSTITUT   (Denmark)

^d MEDICAL RESEARCH COUNCIL   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE;

ANTIBIOTIC RESISTANCE; ARTICLE; CHLAMYDIA TRACHOMATIS; GONORRHEA; HEALTH CARE COST; HUMAN; MOLECULAR DIAGNOSTICS; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; PREDICTIVE VALUE; SEXUALITY; URETHRITIS;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; DRUG RESISTANCE, BACTERIAL; GONORRHEA; HUMANS; INDIVIDUALIZED MEDICINE; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION TECHNIQUES; PREDICTIVE VALUE OF TESTS; TREATMENT FAILURE;

EID: 84895423728     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001598     Document Type: Article

References (38)

1. Davies SC, Fowler T, Watson J, Livermore DM, Walker D, (2013) Annual Report of the Chief Medical Officer: infection and the rise of antimicrobial resistance. Lancet 381: 1606-1609.
2. World Health Organization (2012) Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: World Health Organization.
3. Ison CA, Town K, Obi C, Chisholm S, Hughes G, et al. (2013) Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007-2011. Lancet Infect Dis 13: 762-768.
4. Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, et al. (2011) Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 55: 3538-3545.
5. Tapsall JW, Ndowa F, Lewis DA, Unemo M, (2009) Meeting the public health challenge of multidrug- and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther 7: 821-834.
6. Zappa F (1979) Why does it hurt when I pee? Joe's Garage: Zappa Records.
7. Unemo M, Nicholas RA, (2012) Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 7: 1401-1422.
8. Allen VG, Farrell DJ, Rebbapragada A, Tan J, Tijet N, et al. (2011) Molecular analysis of antimicrobial resistance mechanisms in Neisseria gonorrhoeae isolates from Ontario, Canada. Antimicrob Agents Chemother 55: 703-712.
9. Lewis DA, Sriruttan C, Muller EE, Golparian D, Gumede L, et al. (2013) Phenotypic and genetic characterization of the first two cases of extended-spectrum-cephalosporin-resistant Neisseria gonorrhoeae infection in South Africa and association with cefixime treatment failure. J Antimicrob Chemother 68: 1267-1270.
10. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, et al. (2011) Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 8: e1001067.
11. Diekema DJ, Pfaller MA, (2013) Rapid Detection of Antibiotic Resistant Organism Carriage for Infection Prevention. Clin Infect Dis 56: 1614-1620.
12. Pai NP, Vadnais C, Denkinger C, Engel N, Pai M, (2012) Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries. PLoS Med 9: e1001306.
13. Menzies NA, Cohen T, Lin HH, Murray M, Salomon JA, (2012) Population health impact and cost-effectiveness of tuberculosis diagnosis with Xpert MTB/RIF: a dynamic simulation and economic evaluation. PLoS Med 9: e1001347.
14. Katz AR, Effler PV, Ohye RG, Brouillet B, Lee MV, et al. (2004) False-positive gonorrhea test results with a nucleic acid amplification test: the impact of low prevalence on positive predictive value. Clin Infect Dis 38: 814-819.
15. Klausner JD, (2004) The NAAT is out of the bag. Clin Infect Dis 38: 820-821.
16. Herrmann B, Torner A, Low N, Klint M, Nilsson A, et al. (2008) A new genetic variant of Chlamydia trachomatis in Sweden: National study of impact on detection rates. Emerg Infect Dis 14: 1462-1465.
17. Zenilman JM, Miller WC, Gaydos C, Rogers SM, Turner CF, (2003) LCR testing for gonorrhoea and chlamydia in population surveys and other screenings of low prevalence populations: coping with decreased positive predictive value. Sex Transm Infect 79: 94-97.
18. World Health Organization (2003) Guidelines for the Management of Sexually Transmitted Infections; Revised version 2003. Geneva: World Health Organization.
19. Pitts MK, Smith AMA, Mischewski A, Fairley C, (2005) Men, bodily change and urethritis: a qualitative study. Sex Health 2: 25-28.
20. Bignell C, Unemo M, (2013) 2012 European Guideline on the diagnosis and treatment of gonorrhoea. Int J STD AIDS 24: 85-92.
21. Clark JL, Lescano AG, Konda KA, Leon SR, Jones FR, et al. (2009) Syndromic management and STI control in urban Peru. PLoS One 4: e7201.
22. Whiley DM, Tapsall JW, Sloots TP, (2006) Nucleic acid amplification testing for Neisseria gonorrhoeae: an ongoing challenge. J Mol Diagn 8: 3-15.
23. Dicker LW, Mosure DJ, Steece R, Stone KM, (2007) Laboratory tests used in US public health laboratories for sexually transmitted diseases, 2004. Sex Transm Dis 34: 41-46.
24. Ison CA, (2012) Antimicrobial resistance in sexually transmitted infections in the developed world: implications for rational treatment. Curr Opin Infect Dis 25: 73-78.
25. Sadiq ST, Dave J, Butcher PD, (2010) Point-of-care antibiotic susceptibility testing for gonorrhoea: improving therapeutic options and sparing the use of cephalosporins. Sex Transm Infect 86: 445-446.
26. Ohnishi M, Saika T, Hoshina S, Iwasaku K, Nakayama S, et al. (2011) Ceftriaxone-resistant Neisseria gonorrhoeae, Japan. Emerg Infect Dis 17: 148-149.
27. Young H, Anderson J, Moyes A, McMillan A, (1997) Non-cultural detection of rectal and pharyngeal gonorrhoea by the Gen-Probe PACE 2 assay. Genitourin Med 73: 59-62.
28. Price IH, Menon-Johansson A, Daniels D, (2006) National Audit Group of the British Association for Sexual Health and HIV (2006) A national audit of gonorrhoea management. Int J STD AIDS 17: 133-134.
29. Golden MR, Hughes JP, Cles LE, Crouse K, Gudgel K, et al. (2004) Positive predictive value of Gen-Probe APTIMA Combo 2 testing for Neisseria gonorrhoeae in a population of women with low prevalence of N. gonorrhoeae infection. Clin Infect Dis 39: 1387-1390.
30. Furuya R, Onoye Y, Kanayama A, Saika T, Iyoda T, et al. (2007) Antimicrobial resistance in clinical isolates of Neisseria subflava from the oral cavities of a Japanese population. J Infect Chemother 13: 302-304.
31. Centers for Disease Control and Prevention (2012) Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: Oral Cephalosporins No Longer a Recommended Treatment for Gonococcal Infections MMWR. 61: 590-593.
32. Birkenmeyer L, Armstrong AS, (1992) Preliminary evaluation of the ligase chain reaction for specific detection of Neisseria gonorrhoeae. J Clin Microbiol 30: 3089-3094.
33. Goire N, Freeman K, Tapsall JW, Lambert SB, Nissen MD, et al. (2011) Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol 49: 513-518.
34. Li Z, Yokoi S, Kawamura Y, Maeda S, Ezaki T, et al. (2002) Rapid detection of quinolone resistance-associated gyrA mutations in Neisseria gonorrhoeae with a LightCycler. J Infect Chemother 8: 145-150.
35. Magooa MP, Muller EE, Gumede L, Lewis DA, (2013) Determination of Neisseria gonorrhoeae susceptibility to ciprofloxacin in clinical specimens from men using a real-time PCR assay. Int J Antimicrob Agents 42: 63-67.
36. Balashov S, Mordechai E, Adelson ME, Gygax SE, (2013) Multiplex bead suspension array for screening Neisseria gonorrhoeae antibiotic resistance genetic determinants in noncultured clinical samples. J Mol Diagn 15: 116-129.
37. Goire N, Ohnishi M, Limnios AE, Lahra MM, Lambert SB, et al. (2012) Enhanced gonococcal antimicrobial surveillance in the era of ceftriaxone resistance: a real-time PCR assay for direct detection of the Neisseria gonorrhoeae H041 strain. J Antimicrob Chemother 67: 902-905.
38. Smith R, Coast J, (2013) The true cost of antimicrobial resistance. BMJ 346: f1493.